Xenetic Biosciences' DNase I Data at ASCO Shows Significant CAR-T Enhancement
XBIO sits 71% above its 52-week low of $1.9 on light trading volume (0.4× avg).
Summary
Xenetic Biosciences presented compelling preclinical and translational data at ASCO 2026, demonstrating its DNase I technology significantly enhances CAR-T cell persistence, tumor control, and survival in aggressive hematologic cancer models. This positive development for their immuno-oncology platform follows strong Q1 2026 financial results and a previously announced strategic review. For a micro-cap biotech, these findings validate a key pipeline asset and could materially impact the company's strategic direction and future clinical development.
At the time of this announcement, XBIO was trading at $3.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $1.90 to $13.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.